You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

Article metrics

Article menu

This article has a correction. Please see:

Download PDFPDF

XML
Case report
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

 

Online download statistics by month:

Online download statistics by month: August 2020 to April 2023

AbstractFullPdf
Aug 202010461047209
Sep 2020343343116
Oct 202025525769
Nov 202024224174
Dec 202025125168
Jan 202122422458
Feb 202126826873
Mar 202128128162
Apr 202132932937
May 202119919950
Jun 2021686825
Jul 2021909142
Aug 2021858545
Sep 2021949457
Oct 202111011052
Nov 2021747442
Dec 2021666621
Jan 2022747625
Feb 2022778018
Mar 2022859220
Apr 2022717322
May 2022596022
Jun 2022636717
Jul 202222222620
Aug 2022707217
Sep 2022383917
Oct 2022384119
Nov 2022414314
Dec 202232328
Jan 2023454516
Feb 2023626315
Mar 202372729
Apr 2023293016
Total510351391375